| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.GME.0000222475.93345.B3 |
| P698 | PubMed publication ID | 16735931 |
| P50 | author | The Menopause Society | Q7053808 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| menopause | Q177708 | ||
| P304 | page(s) | 340-67; quiz 368-9 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | Menopause | Q6817295 |
| P1476 | title | Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society | |
| P478 | volume | 13 |
| Q46502403 | A high throughput protein formulation platform: case study of salmon calcitonin |
| Q51663951 | Algorithm for the Management of Osteoporosis |
| Q36520117 | An aerobic weight-loaded pilot exercise intervention for breast cancer survivors: bone remodeling and body composition outcomes |
| Q27013070 | An overview on the treatment of postmenopausal osteoporosis |
| Q36360754 | Approach to the prostate cancer patient with bone disease |
| Q43494844 | Association among menopause, hormone replacement therapy, and periodontal attachment loss in southern Brazilian women. |
| Q45988730 | Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis. |
| Q38160172 | Association of homocysteine, vitamin B12, and folate with bone mineral density in postmenopausal women: a meta-analysis |
| Q36681939 | Association of the MTHFR C677T polymorphism and bone mineral density in postmenopausal women: a meta-analysis |
| Q37698607 | Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis |
| Q37346144 | Bazedoxifene: a selective estrogen-receptor modulator |
| Q33594764 | Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report |
| Q33283991 | Bone mass, bone strength, and their relationship in developing CD-1 mice |
| Q22306250 | Calcium Supplementation in Clinical Practice: A Review of Forms, Doses, and Indications |
| Q36897449 | Clinical challenges in the management of osteoporosis |
| Q47326722 | Clinical practice guideline of traditional medicine for primary osteoporosis |
| Q37911560 | Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines |
| Q35868662 | Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women |
| Q60308270 | Cumulative network-meta-analyses, practice guidelines and actual prescriptions of drug treatments for postmenopausal osteoporosis: a study protocol for cumulative network meta-analyses and meta-epidemiological study |
| Q35059720 | Depression and osteoporosis: a research synthesis with meta-analysis |
| Q37393313 | Depression as a risk factor for osteoporosis |
| Q47205292 | Detective value of historical height loss and current height/knee height ratio for prevalent vertebral fracture in Japanese postmenopausal women |
| Q37297932 | Differences in site-specific fracture risk among older women with discordant results for osteoporosis at hip and spine: study of osteoporotic fractures |
| Q45933090 | Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. |
| Q46855739 | Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study |
| Q44187747 | Effects of electroacupuncture on bone mineral density, oestradiol level and osteoprotegerin ligand expression in ovariectomised rabbits |
| Q40897537 | Effects of plyometric exercise session on markers of bone turnover in boys and young men. |
| Q33861136 | Effects of resistance training and soy isoflavone on body composition in postmenopausal women |
| Q46767327 | Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women |
| Q57220063 | Efficacy and safety of bazedoxifene in postmenopausal Asian women |
| Q46110515 | Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial |
| Q34496410 | Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2 |
| Q24658109 | Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society |
| Q43558031 | Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. |
| Q37614089 | Evaluation of compliance with osteoporosis treatment guidelines after initiation of a pharmacist-run osteoporosis service at a family medicine clinic |
| Q37908104 | Evidence-based risk assessment and recommendations for physical activity: arthritis, osteoporosis, and low back pain |
| Q82329479 | Exercise Promotion: Walking in Elders |
| Q34646272 | Experimental osteoporosis induced by ovariectomy and vitamin D deficiency does not markedly affect fracture healing in rats |
| Q40942151 | Factors affecting bone mineral density in postmenopausal women |
| Q37023421 | Factors associated with a second hip fracture: a systematic review. |
| Q43827197 | Food groups and risk of forearm fractures in postmenopausal women in Chengdu, China |
| Q36951275 | Fracture prevention strategies in patients presenting to Australian hospitals with minimal-trauma fractures: a major treatment gap. |
| Q43715217 | Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. |
| Q58919362 | Healthy Diet to Prevent Cardiovascular Diseases and Osteoporosis |
| Q38032324 | Healthy diet to prevent cardiovascular diseases and osteoporosis: the experience of the 'ProSa' project. |
| Q47354474 | Height loss starting in middle age predicts increased mortality in the elderly |
| Q87763541 | Hepatic magnetic resonance imaging with T2* mapping of ovariectomized rats: correlation between iron overload and postmenopausal osteoporosis |
| Q47285444 | Historical height loss, vertebral deformity, and health-related quality of life in Hiroshima cohort study |
| Q36993374 | Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? |
| Q37354137 | Ibandronate: a review of its use in the management of postmenopausal osteoporosis |
| Q55024426 | Identification of Steroidogenic Components Derived From Gardenia jasminoides Ellis Potentially Useful for Treating Postmenopausal Syndrome. |
| Q61217376 | Incidence of new fractures in women with osteoporosis-induced vertebral fractures detected on routine lateral chest radiographs |
| Q39594889 | Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. |
| Q79416557 | Intravenous ibandronate in the treatment of osteoporosis: profile report |
| Q36586906 | Intravenous ibandronate: in the treatment of osteoporosis |
| Q36823017 | Is treatment of early postmenopausal women with bisphosphonates justified? |
| Q46844849 | Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results |
| Q26853017 | Nuclear receptors in bone physiology and diseases |
| Q36946813 | Osteoporosis guidelines |
| Q34242906 | Osteoporosis therapies: evidence from health-care databases and observational population studies |
| Q37763162 | Osteoporosis update: effective prevention and treatment |
| Q36824450 | Patient assessment in the diagnosis, prevention, and treatment of osteoporosis |
| Q36859988 | Pharmacologic and nonpharmacologic management of osteoporosis |
| Q30542621 | Plasma organochlorine concentrations and bone ultrasound measurements: a cross-sectional study in peri-and postmenopausal Inuit women from Greenland |
| Q37566044 | Prevention, screening, and management of osteoporosis: an overview of the current strategies |
| Q37763796 | Primary antiphospholipid syndrome in premenopausal women: low vitamin D, high fat mass and maintained bone mineral mass |
| Q83891167 | Promoting bone health: focus on postmenopausal women and patients receiving systemic therapy for breast or prostate cancer. Introduction |
| Q36751534 | Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss. |
| Q36897425 | Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis |
| Q46417845 | Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial |
| Q33613016 | Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis |
| Q60923917 | Sharing Pathological Mechanisms of Insomnia and Osteoporosis, and a New Perspective on Safe Drug Choice |
| Q42359031 | Strategy against aging society with declining birthrate in Japan |
| Q37354140 | Teriparatide: a review of its use in osteoporosis. |
| Q35674199 | The effect of breast-feeding duration on bone mineral density in postmenopausal Turkish women: a population-based study |
| Q37052780 | The use of calcium and vitamin D in the management of osteoporosis |
| Q37768158 | Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms |
| Q48915551 | Trends related to aging and co-occurring disorders in HIV-infected drug users |
| Q46222313 | Vitamin D insufficiency does not affect response of bone mineral density to alendronate |
| Q37716669 | What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? |
| Q37306784 | Zoledronic acid: a review of its use in the treatment of osteoporosis |
| Q39329106 | [Menopausal hormone therapy]. |
Search more.